By Dosu Deborah Oluwatimilehin (SIWES student, Adeseun Ogundoyin Polytechnic Eruwa)
In response to recent claims of under-dosed paracetamol drugs circulating in Nigeria, NAFDAC issues a stern warning, refuting the allegations as false and misleading.
Prof. Mojisola Adeyeye, Director-General of NAFDAC, emphasizes the agency’s commitment to ensuring the quality of medicines in Nigeria and urges the public to rely solely on official NAFDAC communications.
A recent study alleged significant discrepancies in the paracetamol content of various brands, prompting concerns about treatment efficacy and consumer safety.
However, NAFDAC asserts that the study’s findings lack validity and have been retracted by the publishing journal. Adeyeye underscores the importance of continued trust in prescribed medication and assures the public of NAFDAC’s ongoing efforts to uphold pharmaceutical standards.
As part of NAFDAC’s rigorous response, Adeyeye’s team conducted comprehensive sampling and testing nationwide, debunking the study’s assertions.
Sampling from major regions like Abuja and Lagos ensured statistically significant results representative of Nigeria’s population. NAFDAC remains steadfast in its mission to safeguard public health and maintain the integrity of pharmaceutical products across the country.
